Table 3

Associations between candidate genes and glioma risk
Genotype Cases, n(%) Controls, n(%) OR (95% CI)a Ptrendb Pvalue for HWE test
XRCC3: rs861539 (T241M)
CC 336 (87.5) 340 (88.5) 1.00 0.835 0.165
CT 47 (12.2) 41 (10.7) 1.15 (0.73-1.79)
TT 1 (0.3) 3 (0.8) 0.33 (0.03-3.22)
XRCC3: rs1799794 (−4541G>A)
GG 100 (26.0) 108 (28.1) 1.00 0.838 0.271
GA 201 (52.4) 181 (47.1) 1.09 (0.78-1.53)
AA 83 (21.6) 95 (24.8) 0.86 (0.57-1.28)
XRCC3: rs1799796 (A17893G)
AA 178 (46.4) 171 (44.5) 1.00 0.231 0.406
AT 173 (45.0) 165 (43.0) 0.97 (0.72-1.31)
TT 33 (8.6) 48 (12.5) 0.64 (0.39-1.04)
BRCA2: rs1799943 (−26G>A)
GG 158 (41.2) 180 (46.9) 1.00 0.149 0.722
GA 186 (48.4) 168 (43.7) 1.22 (0.90-1.64)
AA 40 (10.4) 36 (9.4) 1.22 (0.74-2.01)
BRCA2: rs15869 (3' UTR)
AA 213 (55.5) 220 (57.3) 1.00 0.646 0.375
AC 143 (37.2) 137 (35.7) 1.05 (0.78-1.42)
CC 28 (7.3) 27 (7.0) 1.04 (0.59-1.83)
RAG1: rs2227973 (R820K)
GG 129 (33.6) 134 (34.9) 1.00 1.000 0.586
GA 200 (52.1) 190 (49.5) 0.96 (0.70-1.30)
AA 55 (14.3) 60 (15.6) 0.83 (0.54-1.29)
XRCC5: rs1051685 (3' UTR)
AA 313 (81.5) 326 (84.9) 1.00 0.232 0.808
AG 69 (18.0) 56 (14.6) 1.24 (0.84-1.82)
GG 2 (0.5) 2 (0.5) 1.00 (0.37-2.68)
LIG4: rs1805388 (T9I)
CC 163 (42.4) 222 (57.8) 1.00 < 0.001 0.659
CT 172 (44.8) 142 (37.0) 1.62 (1.20-2.18)
TT 49 (12.8) 20 (5.2) 3.27 (1.87-5.71)
XRCC4: rs1805377 (Splice Site)
AA 179 (46.6) 195 (50.8) 1.00 0.030 0.454
AG 143 (37.2) 153 (39.8) 0.96 (0.71-1.30)
GG 62 (16.2) 36 (9.4) 1.77 (1.12-2.80)
ATM: rs189037 (−111G/A)
GG 140 (36.5) 125 (32.5) 1.00 0.487 0.070
GA 186 (48.4) 203 (52.9) 0.78 (0.57-1.07)
AA 58 (15.1) 56 (14.6) 0.88 (0.57-1.37)

aAdjusted for age, gender, smoking and drinking status.

bFalse Discovery Rate (FDR) corrected P-value.

P < 0.05 for bold significances.

Zhao et al.

Zhao et al. BMC Cancer 2013 13:234   doi:10.1186/1471-2407-13-234

Open Data